ARTICLE | Company News
Actinium, Fred Hutchinson deal
July 16, 2012 7:00 AM UTC
The center granted Actinium worldwide rights to develop and commercialize BC8. The mAb against CD45 is in development to target and eradicate cancerous and other white blood cells in preparation for ...